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Abstract
Cluster of differentiation 47 (CD47) (also known as integrin-associated protein) is a ubiquitously expressed glycoprotein
of the immunoglobulin superfamily that plays a critical role in self-recognition. Various solid and hematologic cancers
exploit CD47 expression in order to evade immunological eradication, and its overexpression is clinically correlated
with poor prognoses. One essential mechanism behind CD47-mediated immune evasion is that it can interact with
signal regulatory protein-alpha (SIRPα) expressed on myeloid cells, causing phosphorylation of the SIRPα cytoplasmic
immunoreceptor tyrosine-based inhibition motifs and recruitment of Src homology 2 domain-containing tyrosine
phosphatases to ultimately result in delivering an anti-phagocytic—“don’t eat me”—signal. Given its essential role as a
negative checkpoint for innate immunity and subsequent adaptive immunity, CD47-SIRPα axis has been explored as a
new target for cancer immunotherapy and its disruption has demonstrated great therapeutic promise. Indeed, CD47
blocking antibodies have been found to decrease primary tumor size and/or metastasis in various pre-clinical models.
In this review, we highlight the various functions of CD47, discuss anti-tumor responses generated by both the innate
and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborate
on the clinical potential of CD47 blockade. We argue that CD47 is a checkpoint molecule for both innate and adaptive
immunity for tumor evasion and is thus a promising target for cancer immunotherapy.
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Background
Cluster of differentiation 47 (CD47), also known as
integrin-associated protein (IAP), is a ~50 kDa heavily gly-
cosylated, ubiquitously expressed membrane protein of the
immunoglobulin superfamily with a single IgV-like domain
at its N-terminus, a highly hydrophobic stretch with five
membrane-spanning segments and an alternatively spliced
cytoplasmic C-terminus [1]. Each of the four alternatively
spliced cytoplasmic tails exists in vivo at different frequen-
cies (i.e., form 2 is the most abundant), but all lack a sub-
stantial signaling domain [2]. While CD47 was first
identified as a membrane protein involved in β3 integrin-
mediated signaling on leukocytes [3], it is now known to
also interact with thrombospondin-1, signal regulatory
protein-alpha (SIRPα), and others to regulate various cellu-
lar functions including cell migration, axon extension, cyto-
kine production, and T cell activation [4–8]. However,
recent studies have focused most on CD47-SIRPα axis for
its inhibitory role in phagocytosis [9]. SIRPα, also known as
Src homology 2 domain-containing protein tyrosine phos-
phatase substrate 1/brain Ig-like molecule with tyrosine-
based activation motif/cluster of differentiation antigen-like
family member A (SHPS-1/BIT/CD172a), is another mem-
brane protein of the immunoglobulin superfamily that is
particularly abundant in the myeloid-lineage hematopoietic
cells such as macrophages and dendritic cells [10, 11]. The
ligation of SIRPα on phagocytes by CD47 expressed on a
neighboring cell results in phosphorylation of SIRPα cyto-
plasmic immunoreceptor tyrosine-based inhibition (ITIM)
motifs, leading to the recruitment of SHP-1 and SHP-2
phosphatases. One resulting downstream effect is the pre-
vention of myosin-IIA accumulation at the phagocytic syn-
apse and consequently inhibition of phagocytosis [12–14].
Thus, CD47-SIRPα interaction functions as a negative
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immune checkpoint to send a “don’t eat me” signal to en-
sure that healthy autologous cells are not inappropriately
phagocytosed. Consistent with this notion, CD47−/− cells
are cleared rapidly when they are adoptively transferred to
the congeneic wild-type mice [15]. However, it was recently
shown that CD47-SIRPα axis, while crucial, represents just
one mechanism that controls phagocytic behavior [16].
Indeed, CD47−/− mice do not manifest significant self-
destruction phenotype unless they are in inflammatory con-
ditions. Inflammatory cytokines stimulate protein kinase C-
spleen tyrosine kinase (PKC-Syk) signaling pathway (which
IL-10 negatively regulates), which then activates macro-
phage to target self cells [16]. Combined, these findings
suggest a potential mechanism for anemia of chronic dis-
ease and that rhesus (Rh)-null individuals, who have <25%
of normal CD47 levels, may be particularly vulnerable to
anemia under inflammatory conditions and infections [17].
Research has demonstrated overexpression of CD47 in
nearly all types of tumors, some of which include acute
myeloid leukemia, non-Hodgkin’s lymphoma, bladder
cancer, and breast cancer [18–25]. While CD47 is impli-
cated in the regulation of cancer cell invasion and me-
tastasis [18, 26], its most well-studied and important
function related to tumor development is prevention of
phagocytosis via ligating with SIRPα on the surrounding
phagocytes [18, 27, 28]. Also, CD47 expression on can-
cer stem cells (CSCs) implies its role in cancer recur-
rence. Particularly, a study has shown that CSCs have
increased CD47 expression to protect themselves from
immune-mediated elimination during conventional anti-
tumor therapies [29]. This increases the chance of CSC
survival, which in turn could repopulate a new tumor
mass and cause a tumor relapse.
CD47 blockade for direct cancer cell killing
Given the important inhibitory function of CD47 in
phagocytosis of tumor cells, it has been extensively inves-
tigated as a potential target for tumor therapy. In various
xenograft tumor models using NOD-scid-IL2Rgammanull
(NSG) mice, use of human CD47-blocking monoclonal
antibodies has demonstrated superb efficacy against hu-
man acute lymphocytic leukemia, acute myeloid leukemia,
leiomyosarcoma, and solid tumors [18, 20, 27, 28, 30, 31].
Most work initially concluded that the therapeutic effects
of anti-human CD47 were dependent on the direct killing
of the tumor by phagocytes. However, it is important to
note that xenograft models might have some unique fea-
tures that favor innate immune-mediated tumor killings.
First, human CD47 binds well to SIRPα of NSG mice, but
not of other strains [32, 33]. This unique feature could put
human tumor cells under CD47-SIRPα control more so in
NSG mice than in other strains of mouse, making them
more susceptible to signaling blockade. Thus, use of hu-
man SIRPα-transgenic recombination-activating gene
(Rag)2−/− IL2Rgamma−/− mice may be necessary to accur-
ately test such antibody’s therapeutic benefit [34]. Second,
in xenograft models, only human tumor cells express hu-
man CD47. Hence, human CD47-blocking monoclonal
antibodies can efficiently target human tumors without
being “absorbed” by other normal cells (such as red blood
cells) expressing mouse CD47. Third, xenograft tissue
could come under strong innate immune attack. For ex-
ample, lacking the mouse MHC class I “self” marker,
xenograft human tumor cells might be attacked by natural
killer (NK) cells if human leukocyte antigen (HLA) fails to
mediate inhibitory signaling. Consistent with this notion,
in syngeneic immunodeficient mouse models such as
athymic nude mice or Rag-deficient mice, mouse anti-
CD47 blockade resulted in less impressive efficacy after
treatment [35]. Fourth, lymphocyte-deficient mice typic-
ally demonstrate stronger innate immune responses [36].
All reasons listed above suggest that contribution of direct
killing by phagocytes to the therapeutic impact of CD47
blockade may be significantly different in an immunocom-
petent organism.
Role of CD8+ T cells upon CD47 blockade
Indeed, adaptive immune response, particularly that
mediated by T cells, plays an important role in mouse
anti-CD47 blockade-induced tumor control. In syngeneic
immunocompetent mouse models, mouse anti-CD47
blockade shows impressive anti-tumor effect especially
upon intratumoral delivery [35, 37]. Depletion of CD8+ T
cells—but not CD4+ T cells—diminishes the therapeutic
effect of anti-mouse CD47 antibody. Furthermore, after
anti-mouse CD47 treatment, significantly more interferon
(IFN)-γ spot-forming antigen-specific CD8+ T cells are
present in the tumor, and T cell-mediated memory re-
sponse is formed to protect mice from tumor re-
challenge. All of these experimental results demonstrate
that T cells are essential for anti-mouse CD47-mediated
tumor regression. Thus, CD47 is a checkpoint molecule
for both innate and adaptive immunity for tumor evasion.
Role of dendritic cells upon CD47 blockade
Since macrophages have been shown to play an import-
ant role in tumor cell phagocytosis in the xenograft
model, they were assumed to be the major antigen-
presenting cells for cytotoxic T lymphocyte (CTL)
induction. Supporting this, enhancement of cross-
priming by macrophages was observed in response to
anti-human CD47 treatment [38]. However, using the
syngeneic mouse model, we have recently shown that den-
dritic cells—not macrophages—appeared to play a more
important role for CTL cross-priming and anti-tumor
therapy based on the following observations [35]. First, in
the presence of anti-mouse CD47 antibody, bone marrow-
derived dendritic cells (BMDCs) were able to cross-prime
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CD8+ T cells to a greater extent than bone marrow-
derived macrophages (BMDMs) in general. Second, ex
vivo isolated dendritic cells (DCs) were more potent for
cross-priming of CTL than macrophages after anti-mouse
CD47 treatment. Third, the therapeutic effect of anti-
mouse CD47 antibody was severely impaired following
DC depletion but not macrophage depletion. Apparent
contradiction between the two studies likely resulted from
differences in experimental approaches. Indeed, when
BMDCs were cultured without serum (similar to in vitro
phagocytosis/priming assays in [38]), they demonstrated
increased apoptosis (as measured by increased annexin V
stain) which would likely impact their functional capacity.
In contrast, macrophages demonstrated very minimal
change in annexin V stain in the presence/absence of the
serum [35].
Also, it seems that although macrophages can phago-
cytose more tumor cells, DCs are more potent than
macrophages in antigen presentation [39]. Macrophages
are good at scavenging and destroying phagocytosed
tumor cells, but at the same time, tumor antigens and
danger signals are overly degraded [39]. In contrast, DCs
have developed means to preserve useful information
from the ingested tumor cells that serve to initiate adap-
tive immune responses [39].
How anti-CD47 blockade boosts DC-mediated antigen
cross-presentation and CTL induction is an intriguing
question that we have started to answer. We found that
after anti-mouse CD47 treatment, DCs—but not macro-
phages—express more Ifna mRNA [35]. Blocking type I
IFN signaling by intratumoral injection of interferon
alpha/beta receptor (IFNAR)-blocking antibody impaired
the therapeutic effect of anti-mouse CD47, suggesting an
important role of type I IFN signaling on DC activation.
Supporting this, conditional deletion of Ifnar 1 in CD11c+
cells markedly reduced the therapeutic effect of CD47
blockade on tumor growth. These data also confirm the
essential role of DCs as antigen-presenting cells (APCs) in
vivo for CTL induction. Interestingly, our data further
demonstrated that cytosolic DNA sensor stimulator of
interferon genes (STING)—but not classical Toll-like
receptor (TLR)-myeloid differentiation primary re-
sponse gene 88 (MyD88) pathway—is required for type
I IFN production and the therapeutic effect of anti-
CD47. This raises a fascinating scenario that upon anti-
CD47 treatment, DNA is released from tumor cells and
taken up by DCs, resulting in the activation of STING
and the production of type I IFN, which activates DCs
for antigen cross-presentation (Fig. 1). The detailed
mechanisms remain to be investigated in the future.
Fig. 1 Working model of CD47 blockade for enhancing antigen cross-presentation by dendritic cells and increased T cell priming. Upon
CD47-SIRPa blockade, tumor cells are phagocytosed and their DNA can gain access to the cytosol of intratumoral dendritic cells. Recognition
of cytosolic DNA by cyclic GMP-AMP (cGAMP) synthase (cGAS) and generation of cGAMP lead to the activation of STING, resulting in the production
of type I IFN. DCs are activated by type I IFN to cross-present tumor antigens to CD8+ T cells, which then proliferate and kill tumor cells
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Targeting CD47-SIRPα signaling axis for therapy
As of November 13, 2016, there are eight phase I clinical
trials that are investigating the effect of blocking CD47-
SIRPα signaling axis in various cancer patients (summa-
rized in Table 1). Among the six, NCT02216409, led by
Forty Seven, Inc., is the first in-human trial and the only
one yet whose data have been presented [40]. Briefly, in
this study, humanized monoclonal anti-CD47 antibody
(“Hu5F9-G4”) [41] was administered to patients with
diverse solid tumors who are no longer candidates for
conventional therapies. As a phase I clinical trial, it
sought to determine the appropriate dosage of Hu5F9-
G4 and to perform the initial pharmacodynamic and
-kinetic studies. Patients tolerated priming (starting)
dose of 0.1, 0.3, and 1 mg/kg well, while those receiving
3 mg/kg experienced a dose-limiting toxicity (abdominal
pain, RBC hemagglutination, and headache). Hence,
1 mg/kg was decided as the priming dose, and currently,
work is being done to determine the optimal mainten-
ance dose. Hu5F9-G4-related adverse events, majority of
which were reversible, included anemia, hyperbilirubine-
mia, headache, hemagglutination, nausea, and retinal
toxicity. It would be interesting to see in the future how
other two therapeutic agents compare to Hu5F9-G4 in
terms of their safety profiles.
It is still unclear, however, if administration of
Hu5F9-G4 alone will result in therapeutic benefits that
are expected based on the promising results of many
pre-clinical studies. Indeed, effective clinical responses
are generally rare and statistically inconclusive in phase
I trials, mainly due to small numbers of patients and in-
ability to optimally administer the therapeutic agent
(i.e., the dosage). Phase II and III trials will be critical
for evaluating the ability to either delay disease progres-
sion or perhaps even cause its remission.
Given that blockade of CD47-SIRPα signaling axis has
(and continues to) demonstrate success in more pre-
clinical tumor models, more entries into clinical trials in-
volving the CD47-SIRPα axis are anticipated. Below, we
offer some suggestions and important considerations to
potentially improve the specificity and efficacy of therapy.
Chemotherapy influences anti-mouse CD47 effects
Many patients might have previously received or continue
to receive chemotherapy during anti-CD47 treatment.
Since chemotherapy can suppress the immune system by
killing recently activated immune cells [42, 43], it is possible
that chemotherapy may blunt the therapeutic effects of
CD47 blockade. However, on the other hand, chemother-
apy may increase the release of tumor antigen and DNA
from dying tumor cells, which may synergize with CD47
blockade. These possibilities have been experimentally eval-
uated [35]. It was found that chemotherapy administered
after anti-CD47 therapy has a detrimental effect on the
development of beneficial anti-tumor memory immune re-
sponses. In contrast, chemotherapy administered before
anti-CD47 therapy not only synergized with anti-CD47 for
tumor control but also preserved the host memory re-
sponse against relapsing tumors. Several possibilities exist
for the synergistic effect of chemotherapy and anti-CD47
treatment. First, chemotherapy may induce the release of
tumor DNA from dying tumor cells, which could augment
STING-mediated cytosolic DNA sensing. Second, chemo-
therapy may sensitize tumor cells by the upregulation of
“eat me” signals, such as surface calreticulin, which could
synergistically amplify the CTL induction in combination
with “don’t eat me” blockade. Third, it is also possible that
the chemotherapy preconditions the tumor microenviron-
ment with more infiltrating inflammatory cells, allowing
Table 1 List of CD47-SIRPα axis-blocking therapeutic agents that are currently being tested in phase I interventional clinical trials
Therapeutic agent(s) Details of the therapeutic
agent
Clinical trial identifiers Study start date Disease in recruited patients
Hu5F9-G4 (NCT02953782
and NCT02953509 use cetuximab
and rituximab, respectively,
in combination)
• Humanized anti-human CD47
monoclonal antibody
• Generated by grafting
complementarity
determining region (CDR)










2. Acute myeloid leukemia
3. Solid malignancy and advanced
colorectal cancer
4. Relapsed/refractory B cell
non-Hodgkin’s lymphoma
TTI-621 • A soluble recombinant
SIRPα-Fc fusion protein
• Generated by combining
the sequences encoding the
N-terminal portion of human






1. Solid malignancy and mycosis
fungoides
2. Hematologic malignancy






1. Solid and hematologic
malignancies
2. Acute myeloid leukemia and
myelodysplastic syndrome
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anti-CD47 blockade to work. Therefore, proper combin-
ation therapy of chemotherapeutic drugs and anti-CD47
antibody may depend on the type, timing, dose of these
agents, and tumor types. Further studies are needed to un-
cover the underlying synergistic mechanisms for a rational
combinational design.
Intratumoral CD47-SIRPα blockade
Given the ubiquitous expression of CD47 on normal cells,
tumor-specific delivery of CD47 blockade would generate
better anti-tumor effect with fewer side effects than sys-
temic administration. Indeed, the possibility of attack
against healthy self cells warrants a concern. For example,
patients, especially those under chronic inflammatory
conditions or infection, may become severely anemic
upon CD47 blockade [16]. Thus, how to block CD47-
SIRPα inside the tumor tissues specifically becomes the
challenge. Tumor-targeting antibodies may be conjugated
with anti-CD47 or SIRPα-Ig to increase specificity [44]. In
the selection of a conjugation partner, two kinds of part-
ners can be exploited. One is pro-phagocytic Fc receptor
(FcR)-activating antibodies, such as the anti-CD20 anti-
body, since CD47-SIRPα interruption can synergize with
antibody-dependent cellular phagocytosis [20, 44]. The
other partner can be adaptive check point blockade anti-
bodies including anti-programmed death ligand 1 (PDL1)
for unleashing both an innate and adaptive anti-tumor re-
sponse [45]. While cytotoxic T lymphocyte-associated
protein 4 (CTLA4) or programmed cell death protein 1
(PD1) blockade monotherapy has gained enormous atten-
tion for its potential to result in a durable clinical response
and prolonged overall survival with tolerable toxicity com-
pared to standard chemotherapy, not all patients respond
[46]. Discovery that nivolumab and ipilimumab dual ther-
apy is more efficacious than ipilimumab monotherapy in
patients with untreated metastatic melanoma highlights
the importance of combination therapy and search for
other molecular targets [47]. It is possible that combin-
ation therapy of anti-CD47 antibody, which increases the
tumor cell phagocytosis and priming of anti-tumor CD8+
T cell responses, and anti-CTLA4/PD1, which reinvigo-
rates exhausted T cells, may give greater synergism by
improving different steps to generating effective anti-
tumor immunity. Such idea that tumor-targeted delivery
of the CD47 checkpoint antagonist can work as a potential
booster to synergize with other tumor-targeting antibodies
for better cancer immunotherapy is being actively investi-
gated, as reflected by phase I clinical trials testing its com-
bination therapy with cetuximab or rituximab (Table 1).
Conclusions
Many solid and hematologic malignancies express CD47
on their cell surface to display an anti-phagocytic signal
to SIRPα-expressing myeloid cells and evade destruction
by innate and adaptive immune system. Administration
of anti-CD47 blocking antibodies has been enormously
successful in various pre-clinical models, mechanism of
which likely involves both phagocyte-mediated direct
killing and their cross-priming of cytotoxic T cells. Our
recent work has illustrated a critical role for dendritic
cells and the STING pathway, as well as CD8+ T cells, to
achieving therapeutic effect of CD47 blockade. Cur-
rently, there are eight clinical trials in progress related to
CD47-SIRPα blockade and more entries are anticipated.
In the future, a combinational design including anti-
CD47 antibody with appropriate chemotherapy and
immune-modulating agents such as anti-tumor anti-
bodies, type I IFN, STING agonists, immune checkpoint
modulators, and others should be intensely investigated
for achieving synergistic and tumor-specific effect for
clinical application.
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